Arcadia Biosciences, Inc.

RKDA Consumer Defensive Packaged Foods

Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 35.9% and free cash flow grew 82.1%, each against the same quarter a year earlier.

0.16 0.04 −20.00%
Market cap
$490.0K
P/E
0.0×
Fwd P/E
−1.5×
Dividend yield
—
F-score
3/9
Altman Z
−59.20
Beneish M
−1.84
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
4 5 2 1 4 2 4 2 3 3
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
(3.03) (15.07) (11.02) (9.13) (5.54) (7.86) (12.46) (19.08) (28.14) (59.20)
P/S ratio
12.53 2.89 8.16 29.83 3.14 3.26 0.90 0.81 1.60 0.56
Altman Z″-Score (non-manufacturers)
(4.57) (33.17) (22.31) (19.79) (11.29) (15.14) (24.78) (41.36) (64.94) (136.50)
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.51
P/Operating CF
(9.34) (4.34) (4.43) (6.96) (3.73) (3.32) (2.85) (0.87) (3.65) (3.15)
Beneish M-Score
(3.42) (1.79) (3.67) (0.32) 5.55 — (3.57) (0.63) 0.68 (1.84)
P/B ratio
1.80 1.45 0.93 4.19 0.88 0.71 0.32 0.28 1.30 0.65
Price to Tangible BV
1.80 1.45 0.93 4.19 0.91 0.72 0.32 0.28 1.30 0.66
EV/Sales
4.56 4.89 7.64 8.28 0.35 (0.95) (1.86) (1.78) 0.78 (0.36)
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.23 1.13 1.55 0.00 0.72
EV/Operating CF
(0.85) (1.41) (0.82) (0.56) (0.09) 0.25 0.99 0.52 (0.41) 0.37
EV/FCF
(0.84) (1.40) (0.81) (0.52) (0.09) 0.24 1.05 0.52 (0.42) (1.61)
Quick Ratio
16.33 4.04 7.20 4.54 4.29 5.96 5.19 3.38 2.11 2.42
Current Ratio
16.69 4.27 7.49 4.98 5.02 7.02 6.03 4.17 3.61 3.09
Net Debt/EBITDA
1.40 0.92 1.29 1.35 2.02 1.02 1.69 2.27 1.40 1.89
Debt/Assets
44.41% 0.00% 0.00% 0.40% 6.86% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
1.13 0.00 0.00 0.02 0.11 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.05 0.11 0.07 0.04 0.20 0.15 0.20 0.18 0.30 0.48
Operating CF/Net income
0.87 0.89 1.01 0.60 6.49 1.76 0.91 1.09 1.37 2.03
Capex/Depreciation
(0.52) (0.39) 6.15 (2.02) (1.40) (0.14) 0.48 0.11 7.10 8.82
Interest Coverage
(14.12) (19.16) — (3,876.20) (271.87) (1,776.30) 48.47 — — —
ROE
(62.87%) (104.00%) (129.48%) (272.50%) (25.25%) (49.07%) (59.03%) (83.21%) (74.37%) (45.14%)
ROA
(30.00%) (42.95%) (66.41%) (101.79%) (11.65%) (32.13%) (42.22%) (57.50%) (42.37%) (23.32%)
ROIC
0.00% 0.00% 0.00% 0.00% (130.26%) (884.26%) (3,419.68%) (359.45%) (115.09%) 0.00%
Return on Tangible Assets
(39.56%) (132.87%) (66.68%) (117.42%) (16.10%) (44.92%) (70.31%) (122.08%) (104.73%) (54.33%)
Average Days of Receivables
61.02 111.97 41.89 187.96 63.88 73.75 60.08 41.47 85.01 31.93
Research and Development Expense of Revenue
271.74% 183.98% 414.55% 607.19% 99.08% 57.36% 20.34% 1.44% 1.05% 0.19%
Selling, General and Administrative Expense of Revenue
384.25% 264.56% 792.62% 1,160.56% 204.97% 338.32% 202.70% 184.87% 191.10% 144.11%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.02 0.01 0.00 0.00 0.00 0.01
Share Based Compensation of Revenue
33.22% 36.61% 105.87% 195.64% 25.42% 22.73% 14.91% 16.10% 10.15% 4.82%
Graham Net Nets
0.45 0.56 0.98 0.12 0.51 1.02 2.59 2.21 0.24 1.46
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(48.89%) (136.85%) (192.11%) (83.21%) (17.79%) (62.50%) (231.34%) (489.35%) (87.18%) (86.36%)
Free Cash Flow Yield
(43.26%) (120.59%) (116.13%) (53.50%) (129.15%) (121.35%) (195.70%) (421.82%) (115.37%) 39.84%
Revenue per Share
57.44 74.69 15.54 7.35 32.27 12.74 12.38 3.60 3.70 3.55
Operating CF per Share
(307.30) (259.09) (144.70) (108.10) (121.36) (48.62) (23.33) (12.36) (7.06) (3.46)
Capex per Share
(4.16) (1.39) (2.55) (9.18) (9.35) (1.86) 1.42 0.09 3.17 0.55
Free Cash Flow per Share
(311.46) (260.48) (147.25) (117.28) (130.70) (50.48) (21.92) (12.27) (3.90) (2.92)
Cash per Share
910.99 241.61 231.67 159.22 103.08 53.92 34.46 9.41 3.11 3.34
Shareholders Equity per Share
399.96 148.55 136.04 52.33 114.67 58.64 34.89 10.27 4.57 3.03
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
399.96 148.55 136.04 52.33 114.67 58.64 34.89 10.27 4.57 3.03
Free Cash Flow
(17.29) (14.04) (13.87) (18.66) (32.54) (26.86) (13.13) (15.18) (5.31) (3.99)
Working Capital
49.09 11.52 19.82 22.73 25.38 30.35 21.19 11.38 6.68 4.30
Capital Expenditures
(0.23) (0.07) (0.24) (1.46) (2.33) (0.99) 0.85 0.11 4.32 0.75
Net Current Asset Value
17.85 6.48 11.67 4.19 12.90 22.67 17.38 7.97 1.95 3.95
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.18 0.99 1.30 0.00 0.70
Capex to Sales
0.07 0.02 0.16 1.25 0.29 0.15 (0.11) (0.02) (0.86) (0.15)
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.87 0.64 (0.10) 0.40 0.47 3.17 2.60 14.06 14.83 10.63
Cash ROIC
(17.66%) (66.76%) (40.05%) (55.22%) (56.63%) (44.85%) (31.60%) (62.37%) (50.73%) (45.83%)
Accounts Receivable Turnover
4.83 4.55 2.09 3.04 8.00 4.88 5.73 5.16 6.00 6.07
Accounts Payable Turnover
0.37 0.12 0.26 0.24 1.18 2.25 1.88 0.91 1.47 1.59
Inventory Turnover
3.28 1.18 3.22 0.90 1.85 2.11 1.81 1.38 3.40 2.93
Average Days of Payables
962.05 3,219.22 1,460.55 1,932.23 288.19 152.49 170.80 320.68 259.68 210.78
Days of Inventory on Hand
102.77 295.35 99.95 739.90 267.62 185.81 138.86 140.53 111.36 142.80
Average Receivables
0.66 0.88 0.70 0.39 1.00 1.39 1.30 0.86 0.84 0.80
Average Payables
2.39 2.43 2.57 3.67 4.40 3.87 3.25 2.38 2.01 1.95
Average Inventory
0.27 0.24 0.21 0.99 2.80 4.12 3.38 1.58 0.87 1.06
Average Assets
65.41 36.57 20.30 28.30 39.96 45.63 36.42 24.31 16.61 10.03
Average Common Equity
31.21 15.10 10.41 10.57 18.44 29.87 26.05 16.80 9.46 5.18

Fold the line items

Columns are period end dates